Navigation Links
U of MN study shows link between gene variations and cancer survival

Scientific research shows that certain genes can influence a person's likelihood to contract particular diseases, cancer for example. New research at the Masonic Cancer Center, University of Minnesota demonstrates that genetic markers may also show a person's likelihood to survive the disease.

A research study led by Brian Van Ness, Ph.D., has successfully identified combinations of genes associated with early clinical relapse of multiple myeloma, a cancer of the white blood cells that produce antibodies. These results raise the possibility that a patient's genetic background exerts an important influence on the patient's prognosis and response to treatment.

"Ultimately, the goal of this research is to predict drug efficacy and toxicity based on a patient's genetic profile, and develop individualized assessments and predictions for the right drug, at the right dose, for the right patient," Van Ness said. This approach offers the dual benefits of avoiding unnecessary treatment for patients less likely to respond to a particular drug, and targeting treatments to those who will benefit most.

The findings are reported in the current issue of the research journal BMC Medicine. Van Ness heads the University's Department of Genetics, Cell Biology, and Development, and conducts research through the Masonic Cancer Center.

In this study, Van Ness and his colleagues used genetic information that the International Myeloma Foundation has gathered from myeloma patients worldwide through its program, Bank On A Cure. This first-of-its-kind program involves several of the major treatment and research centers for myeloma worldwide and thousands of myeloma patients who donate DNA samples to the bank. The University of Minnesota houses one of the program's two DNA banks (the other is in London), and Van Ness is co-director of the program.

"Although myeloma is considered a fatal disease, individual patients have widely varied rates of disease progression and response to treatment because of attributes encoded in their DNA," Van Ness said.

According to Van Ness, the research study findings demonstrate that cancer outcomes differ because patients vary in the ways they absorb, distribute, metabolize, and transport drugs across cell membranes. Individual variations in genes that regulate these biologic processes may not only affect the effectiveness of the drug, but also can result in adverse side effects.

The findings from this study pave the way for similar investigations into other cancers, neurological and cardiovascular conditions, organ transplants, and other diseases.


Contact: Sara Martin
University of Minnesota

Related biology news :

1. NOAA and NSF commission national study of ocean acidification
2. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
3. New CU-Boulder study shows diversity decreases chances of parasitic disease
4. UCSF Fresno leading-edge study lends hope to emphysema patients
5. Study sheds new light on dolphin coordination during predation
6. Current mass extinction spurs major study of which plants to save
7. Study: Wildlife need more complex travel plans
8. UGA study reveals ecosystem-level consequences of frog extinctions
9. Study links nicotine with breast cancer growth and spread
10. Study finds high mortality of endangered loggerhead sea turtles in Baja California
11. Landmark study unlocks stem cell, DNA secrets to speed therapies
Post Your Comments:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
(Date:6/22/2016)... 2016  According to Kalorama Information, the dominant ... market include significant efforts in automation as well ... and affordable sequencers, say the healthcare market research ... including sample prep materials.  The healthcare market research ... for Next Generation Sequencing (NGS) , highlights major ...
Breaking Biology Technology: